These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23290729)

  • 1. Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook.
    Dwyer JP; Lewis JB
    Med Clin North Am; 2013 Jan; 97(1):53-8. PubMed ID: 23290729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
    Steinke JM; Mauer M;
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Developmental phases and diagnostic criteria in diabetic nephropathy].
    Duława J
    Pol Tyg Lek; 1990 Oct 1-8; 45(40-41):807-9. PubMed ID: 2096373
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes.
    Nosadini R; Brocco E
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():1-7. PubMed ID: 9288531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of microscopic haematuria in diabetic nephropathy in type 2 diabetes patients with overt proteinuria.
    Okada T; Nagao T; Matsumoto H; Nagaoka Y; Wada T; Nakao T
    Nephrology (Carlton); 2013 Aug; 18(8):563-8. PubMed ID: 23714217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diabetic nephropathy and molecular biology of the renin-angiotensin system in the diabetic kidney].
    Rodríguez Pérez JC; Barrio Castellanos R
    Med Clin (Barc); 1995 Nov; 105(18):708-15. PubMed ID: 8538254
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical manifestations and natural history of diabetic kidney disease.
    Ritz E
    Med Clin North Am; 2013 Jan; 97(1):19-29. PubMed ID: 23290727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic nephropathy--are there differences between type I and type II?
    Ritz E; Hasslacher C; Tschöpe W
    Miner Electrolyte Metab; 1990; 16(1):69-72. PubMed ID: 2182996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse models of diabetic nephropathy.
    Breyer MD; Böttinger E; Brosius FC; Coffman TM; Harris RC; Heilig CW; Sharma K;
    J Am Soc Nephrol; 2005 Jan; 16(1):27-45. PubMed ID: 15563560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of intrarenal renin-angiotensin system activity in diabetic versus non-diabetic patients with overt proteinuria.
    Park JH; Jang HR; Lee JH; Lee JE; Huh W; Lee KB; Kwon YJ; Do JY; Kim HY; Kim YG
    Nephrology (Carlton); 2015 Apr; 20(4):279-85. PubMed ID: 25522682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical indicators which necessitate renal biopsy in type 2 diabetes mellitus patients with renal disease.
    Lin YL; Peng SJ; Ferng SH; Tzen CY; Yang CS
    Int J Clin Pract; 2009 Aug; 63(8):1167-76. PubMed ID: 18422591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of diabetic nephropathy.
    Raptis AE; Viberti G
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S424-37. PubMed ID: 11460589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased prevalence of proliferative retinopathy and cardiovascular autonomic dysfunction in IDDM patients with proteinuria.
    Zander E; Seidlein I; Herfurth S; Heinke P; Chlup R; Badendick K; Strese J; Zander G; Schulz B
    Exp Clin Endocrinol; 1992; 99(2):102-7. PubMed ID: 1639116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and histological correlation of diabetic nephropathy.
    Afroz T; Sagar R; Reddy S; Gandhe S; Rajaram KG
    Saudi J Kidney Dis Transpl; 2017; 28(4):836-841. PubMed ID: 28748886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.